|
|
|
|
|
Idarubicin
drug data and news
Idarubicin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Idarubicin | ||
| Brand Names/Synonyms | IDARUBICIN; Idamycin; Idamycin Pfs; Idarubicin; Idarubicin Aglycone; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin Hydrochloride; Idarubicina [Inn-Spanish]; Idarubicine [Inn-French]; Idarubicinum [Inn-Latin] | ||
| Indication | For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Idarubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Idarubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Idarubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific. | ||
| Mechanism Of Action | Idarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. | ||
| Idarubicin News (When available) |
| ||
| Dosage Forms | POWDER FOR SOLUTION | ||
| Drug_Category | Antibiotics; Antineoplastic Agents; ATC:L01DB06 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Idarubicin: No Information Provided. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione | ||
| Chemical Formula | C26H27NO9 | ||
| Molecular Weight | 497.494 g/mol | ||
| Smiles String | CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 0.803 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 22 hours | ||
| Protein Binding [%] | 97% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Idarubicin.html http://www.rxlist.com/cgi/generic2/idarubicin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00126 | ||
| CAS Registry Number | 58957-92-9 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:183368 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2065630 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |